scholarly journals Unlabeled oligonucleotide probes modified with locked nucleic acids for improved mismatch discrimination in genotyping by melting analysis

BioTechniques ◽  
2005 ◽  
Vol 39 (5) ◽  
pp. 644-650 ◽  
Author(s):  
Lan-Szu Chou ◽  
Cindy Meadows ◽  
Carl T. Wittwer ◽  
Elaine Lyon
2021 ◽  
Vol 22 (7) ◽  
pp. 3526
Author(s):  
Takenori Shimo ◽  
Yusuke Nakatsuji ◽  
Keisuke Tachibana ◽  
Satoshi Obika

Our group previously developed a series of bridged nucleic acids (BNAs), including locked nucleic acids (LNAs), amido-bridged nucleic acids (AmNAs), and guanidine-bridged nucleic acids (GuNAs), to impart specific characteristics to oligonucleotides such as high-affinity binding and enhanced enzymatic resistance. In this study, we designed a series of LNA-, AmNA-, and GuNA-modified splice-switching oligonucleotides (SSOs) with different lengths and content modifications. We measured the melting temperature (Tm) of each designed SSO to investigate its binding affinity for RNA strands. We also investigated whether the single-stranded SSOs formed secondary structures using UV melting analysis without complementary RNA. As a result, the AmNA-modified SSOs showed almost the same Tm values as the LNA-modified SSOs, with decreased secondary structure formation in the former. In contrast, the GuNA-modified SSOs showed slightly lower Tm values than the LNA-modified SSOs, with no inhibition of secondary structures. We also evaluated the exon skipping activities of the BNAs in vitro at both the mRNA and protein expression levels. We found that both AmNA-modified SSOs and GuNA-modified SSOs showed higher exon skipping activities than LNA-modified SSOs but each class must be appropriately designed in terms of length and modification content.


2004 ◽  
Vol 328 (2) ◽  
pp. 244
Author(s):  
Luis A. Ugozzoli ◽  
David Latorra ◽  
Randi Puckett ◽  
Khalil Arar ◽  
Keith Hamby

2004 ◽  
Vol 324 (1) ◽  
pp. 143-152 ◽  
Author(s):  
Luis A Ugozzoli ◽  
David Latorra ◽  
Randi Pucket ◽  
Khalil Arar ◽  
Keith Hamby

2017 ◽  
Vol 121 (12) ◽  
pp. 2594-2602 ◽  
Author(s):  
Xiaoping Olson ◽  
Shohei Kotani ◽  
Bernard Yurke ◽  
Elton Graugnard ◽  
William L. Hughes

Biomedicines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 416
Author(s):  
Saumya Jani ◽  
Maria Soledad Ramirez ◽  
Marcelo E. Tolmasky

Antisense technologies consist of the utilization of oligonucleotides or oligonucleotide analogs to interfere with undesirable biological processes, commonly through inhibition of expression of selected genes. This field holds a lot of promise for the treatment of a very diverse group of diseases including viral and bacterial infections, genetic disorders, and cancer. To date, drugs approved for utilization in clinics or in clinical trials target diseases other than bacterial infections. Although several groups and companies are working on different strategies, the application of antisense technologies to prokaryotes still lags with respect to those that target other human diseases. In those cases where the focus is on bacterial pathogens, a subset of the research is dedicated to produce antisense compounds that silence or reduce expression of antibiotic resistance genes. Therefore, these compounds will be adjuvants administered with the antibiotic to which they reduce resistance levels. A varied group of oligonucleotide analogs like phosphorothioate or phosphorodiamidate morpholino residues, as well as peptide nucleic acids, locked nucleic acids and bridge nucleic acids, the latter two in gapmer configuration, have been utilized to reduce resistance levels. The major mechanisms of inhibition include eliciting cleavage of the target mRNA by the host’s RNase H or RNase P, and steric hindrance. The different approaches targeting resistance to β-lactams include carbapenems, aminoglycosides, chloramphenicol, macrolides, and fluoroquinolones. The purpose of this short review is to summarize the attempts to develop antisense compounds that inhibit expression of resistance to antibiotics.


2003 ◽  
Vol 17 (4) ◽  
pp. 165-169 ◽  
Author(s):  
Asli N Silahtaroglu ◽  
Niels Tommerup ◽  
Henrik Vissing

2003 ◽  
Vol 10 (3-4) ◽  
pp. 325-334 ◽  
Author(s):  
Henrik Ørum ◽  
Andreas Wolter ◽  
Lars Kongsbak

2006 ◽  
Vol 24 (2) ◽  
pp. 171-182 ◽  
Author(s):  
Thomas K. Ormond ◽  
Daniel Spear ◽  
Jacqueline Stoll ◽  
Megan A. Mackey ◽  
Pamela M. St. John

Sign in / Sign up

Export Citation Format

Share Document